Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole effect on DZD8586 PK in healthy participants
NCT07888569Phase 1Not yet recruiting
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Oct 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of birelentinib in B-cell non-Hodgkin lymphoma, sponsored by Dizal Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Curve from Time Zero to Infinity of DZD8586 at 120 hours, Area Under the Curve from Time Zero to Last Quantifiable Concentration of DZD8586 at 120 hours and 1 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
birelentinib
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07888569.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07888569.